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1. Introduction
The association between Charcot neuroarthropathy (CN) and diabetes mellitus was first
described by Jordan in 1936 (Jordan WR, 1936). Since that time numerous treatment protocols
have been proposed for this potentially devastating condition. Early diagnosis and swift care
are the keys to reducing amputation risk in this patient population. Conservative management
remains efficacious for certain clinical scenarios. Treatment of the patient should take into
account the stage of CN, site(s) of involvement, presence or absence of ulceration, presence or
absence of infection, overall medical status, and level of compliance. The most commonly used
classification is the three-staged system described by Eichenholtz: Stage I is the developmental
or acute phase, Stage II is the coalescent or quiescent phase, and Stage III is the consolidation
or reconstruction and reconstitution phase (Eichenoltz SN, 1966). Involvement of the midfoot
is most common in the diabetic population and this site tends to be more amenable to conser‐
vative options versus hindfoot or ankle CN. Generally, conservative care for the CN foot and
ankle has been recommended for the following scenarios: joints in the acute phase, deformities
that are clinically stable and that do not compromise the soft tissue envelope, stable deformities
without soft tissue or bone infection, patients who do not have adequate arterial perfusion to
support surgical reconstruction, and those patients who are extremely high risk for anesthesia
and surgical intervention due to the presence of multiple severe comorbid conditions. In this
© 2013 Grover Páez et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
chapter we present an overview of evidence-based non-operative treatment for CN with an
emphasis on the most recent developments in therapy.
2. Clinical presentation
Acute diabetic neuroarthropathy may evolve slowly over many months or develop rapidly
within weeks (Rajbhandari SM et al., 2002; Pogonowska MJ et al., 1967). The process begins
with a  hyperemia usually following trauma to the foot  or  ankle (Yu GV & Hudson JR,
2002). The trauma is often mild and may not even be recalled by the patient (Sanders LJ
& Frykberg  RG,  1993;  Rajbhandari  SM et  al.,  2002;  Armstrong  DG & Peters  EJG,  2002;
Armstrong  DG  et  al.,  1997).  Not  infrequently  there  may  be  a  delay  of  several  months
between the trauma and the incipient neuroarthropathy (Sanders LJ & Frykberg RG, 1993).
Classical clinical findings are an edematous, warm foot with bounding pulses and a severe
peripheral neuropathy. The normal architecture of the foot may be disturbed and plantar
ulceration at the site of deformity may be present. Most patients complain of pain, but the
complaints are usually less than would be expected from the clinical findings (Sanders LJ
& Frykberg RG, 1993; Rajbhandari SM et al., 2002; Armstrong DG & Peters EJG, 2002). Men
and women are equally affected.  Most  patients  are  in the mid-fifties,  but  neuroarthrop‐
athy can occur at  any age (Sanders LJ & Frykberg RG, 1993).  Unilateral  development is
most  common,  but  a  significant  number  of  patients  can  develop  bilateral  involvement
(Sanders LJ & Frykberg RG, 1993; Fabrin J et al.,  2000).  Patients with long-standing (>10
years) and poorly controlled diabetes, neuropathy, history of ulceration, recent history of
trauma,  prior  neuroarthropathy,  or  renal  transplantation  are  high  risk  and  should  be
watched closely since early clinical findings may be mild (Sanders LJ & Frykberg RG, 1993).
However,  the  acute  phase  of  CN often  goes  unnoticed,  resulting  in  a  delayed  positive
diagnosis and progression to the chronic phase, with irreversible deformation. The main
problem is that, at this stage of the disease, not only is the clinical diagnosis not easy to
make,  but  standard  radiography  often  cannot  distinguish  acute  CN  from  other  condi‐
tions.  Indeed,  X-ray radiography may fail  to  document  any evidence of  fracture  and/or
dislocation. Radioisotope technetium (Tc-99m) bone scintigraphy has good sensitivity, but
poor specificity, for osseous pathology and only shows increased focal uptake during the
bony phase.
Only magnetic resonance imaging (MRI) is capable of revealing, in greater detail, the nature
of  the  bony  damage  and  evidence  of  inflammation  in  the  bone  (subchondral  bone-
marrow  oedema  with  or  without  microfracture)  as  well  as  in  the  adjacent  soft  tissues
(Edmonds ME et al., 2005; Chantelau E & Poll LW, 2006). MRI is particularly useful in the
earliest stages of the disease, as there is a significant correlation between the intensity of
bone-marrow oedema and clinical parameters such as soft-tissue oedema or pain (Schloss‐
bauer T et al., 2008).
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Figure 1. The right foot (plantar and lateral views) of a 59-year-old man with diabetic neuropathy showing collapse of
the internal arch (arrow) and a large neuropathic ulcer on the midplantar surface. (B) Computed tomographic images
(dorsoplantar and lateral views) of the patient’s right foot showing a subchondral cyst (arrow), fragmentation, disor‐
ganization, and loss of normal architecture of the talus, calcaneus, tarsal bones and bases of the metatarsals. (Nicola
Mumoli MD & Alberto Camaiti MD, 2012).
3. Classification
Different systems have been proposed to classify CN, and the one most commonly used is an
anatomically based system, the Sanders–Frykberg anatomical classification that divides the
foot into five zones, according to the joints involved (Sanders LJ & Frykberg RG, 1991):
Type I: involves the metatarsophalangeal and interphalangeal joints
Type II: involves the tarsometatarsal joints
Type III: involves the tarsal joints
Type IV: involves the subtalar joints
Type V: involves the calcaneum.
This classification has proved especially helpful in predicting prevalence and prognosis. Types
I and II are the most common types, while types II and III are particularly associated with the
risk of abnormal friction and ulceration, and types IV and V carry poor prognoses due to the
effects of weight distribution during walking as shown in table 1, (Edmonds ME et al., 1985).
The most common classification of Charcot osteo-arthropathy follows the natural history of
Charcot and was originally described by (Sidney Eichenholtz S.N, 1966). This classification
incorporates both a clinical and a radiographic evaluation of the patient Table 2:
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Pattern Location % of cases Common findings
I Forefoot 35 Atrophic destruction: resorption of metatarsal and
phalangeal shafts, osteolysis, subluxation of
metatarsophalangeal joints, plantar ulceration
II Tarsometatarsal joint 30 Subluxation of metatarsal bases, Rocker-bottom
deformity, plantar ulceration, chronic instability
III Talonavicular, calcaneocuboid
and naviculocuneiform joint
25 Osteolysis of naviculocuneiform joint, Rocker-bottom
deformity, often found in conjunction with Pattern II
IV Ankle joint 9 Extensive joint destruction, severe deformity and
instability, risk of high level amputation
V Calcaneus 1 No joint involvement, calcaneal insufficiency avulsion
fracture
Table 1. Sanders-Frykberg anatomical classification of neuroarthorpathy.
Pattern Location % of cases Common findings
I Forefoot 35 Atrophic destruction: resorption of metatarsal and
phalangeal shafts, osteolysis, subluxation of
metatarsophalangeal joints, plantar ulceration
II Tarsometatarsal joint 30 Subluxation of metatarsal bases, Rocker-bottom
deformity, plantar ulceration, chronic instability
III Talonavicular, calcaneocuboid
and naviculocuneiform joint
25 Osteolysis of naviculocuneiform joint, Rocker-bottom
deformity, often found in conjunction with Pattern II
IV Ankle joint 9 Extensive joint destruction, severe deformity and
instability, risk of high level amputation
V Calcaneus 1 No joint involvement, calcaneal insufficiency avulsion
fracture
Table 2. Add caption
Stage 0 has been added to the classification by Schon and Marks in 1995 in an attempt to indicate
the high risk of developing an acute Charcot osteo-arthropathy following a traumatic event.
(Schon LC et al., 1998; Brodsky JW, 1999).
4. Pathogenesis
The Charcot foot has been documented to occur as a consequence of various peripheral
neuropathies; however, diabetic neuropathy has become the most common etiology. The
interaction of several component factors (diabetes, sensory-motor neuropathy, autonomic
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neuropathy, trauma, and metabolic abnormalities of bone) results in an acute localized
inflammatory condition that may lead to varying degrees and patterns of bone destruction,
subluxation, dislocation, and deformity.
This inflammation leads to osteolysis and is indirectly responsible for the progressive fracture
and dislocation (Uccioli L et al., 2010; La Fontaine J et al., 2008). When a bone is fractured, the
release of proinflammatory cytokines including tumor necrosis factor- α and interleukin-1β
leads to increased expression of the polypeptide receptor activator of nuclear factor-Kb ligand
(RANKL) from any of a number of local cell types. RANKL triggers the synthesis of the nuclear
transcription factor nuclear factor-kb (NF-kb), and this in turn stimulates the maturation of
osteoclasts from osteoclast precursor cells. At the same time, NF-kb stimulates the production
of the glycopeptide osteoprotegerin (OPG) from osteoblasts. This “decoy receptor” acts as an
effective antagonist of RANKL (Mabilleau G et al., 2008). It has been suggested that this results
in continual production of proinflammatory cytokines, RANKL, NF-kb, and osteoclasts, which
in turn leads to continuing local osteolysis (La Fontaine J et al., 2008). Osteoclasts generated in
vitro in the presence of macrophage colony-stimulating factor and RANKL from patients with
active CN have been shown to be more aggressive and exhibit an increase in their resorptive
activity that peptides normally secreted from nerve terminals are also important in the
underlying pathophysiology. Of these, calcitonin gene-related peptide (CGRP) is a likely
candidate because it is known to antagonize the synthesis of RANKL.
The receptor activator of the nuclear factor-ligand (RANKL)-activated peripheral blood
monocytes have been found to induce a significant increase in bone resorption in Charcot
patients (Mabilleau G et al., 2008; Jeffcoate W et al., 2004).
A possible link between proinflammatory cytokines and neuroarthropathy in the context of
an exaggerated inflammatory response to trauma has been mentioned (Jeffcoate WJ et al,
2005), and the inability of the Charcot patient to control the intensity and the length of the local
inflammatory response would lead to increased expression of tumor necrosis factor-α (TNF-
α) and interleukin-1(IL-1) which, in turn, would trigger increased expression of RANKL
leading to maturation of osteoclast and subsequent bone changes (Lam J et al., 2002; Boyle WJ
et al., 2003).
The immune phenotype of monocytes was assessed by testing spontaneous and induced
production of proinflammatory and anti-inflammatory cytokines by measuring the expression
of surface molecules (CD40, CD80, and CD86), which enable monocytes to became competent
co-stimulatory cells and to activate T lymphocytes responses (Jenkins MK et al 2001; Kuchroo
VK et al., 1995; Yang Yet al., 1996), and by studying the ability of monocytes to undergo
apoptosis, an important homeostatic mechanism that contributes to regulate the intensity and
length of the inflammatory response (Gonzalez-Mejia ME & Doseff AI, 2009). Patients with
acute Charcot, in both the active and recovered phase, peripheral monocytes acquire a
proinflammatory immune phenotype characterized by increased production of proinflamma‐
tory cytokines, reduced secretion of anti-inflammatory cytokines, increased expression of co-
stimulatory surface molecules, and increased resistance to apoptosis. Monocytes play a pivotal
role in the development and maintenance of the inflammatory response. These cells are the
major source of proinflammatory (TNF- α, IL-1, and IL-6) as well as anti-inflammatory
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cytokines (IL-4 and IL-10) (Kiener PA et al., 1995; Gautam SC et al., 1992; De Waal Malefyt R
et al., 1991).
Alterations in the correct timing, intensity, and balance of expression of proinflammatory
versus anti-inflammatory cytokines by monocytes result in pathologic modulation of the
inflammatory response. Thus, the activation of inflammatory and suppression of anti-
inflammatory cytokines that we have found in patients with acute Charcot is consistent with
the abnormally intense and prolonged inflammatory response that characterizes the acute
phase of this disease. A growing body of evidence is now supporting the possibility that this
inflammatory response plays a pivotal pathogenetic role in the changes in bone and joints that
develop in this disorder (Jeffcoate WJ et al., 2005). Indeed, TNF-α and IL-1, released during
the inflammatory process, trigger increased expression of RANKL (Lam J et al., 2002; Xu J et
al., 2009).
This leads to activation of NFk-b and maturation of osteoclasts (Hofbauer LC et al 2000; Boyle
WJ et al 2003). The effect of IL-6 on bone formation/resorption is more controversial. Indeed,
several reports support the possibility that IL-6 could in fact induce an osteocytic phenotype
(Chipoy C et al., 2004). As opposed, there is evidence that IL-6 can stimulate osteoclasts
differentiation and bone resorption by an indirect mechanism, increasing interactions between
osteoblasts and osteoclasts (Palmqvist Pet al 2002; Sinistro A et al., 2008).
The proinflammatory alterations we have found in the phenotype of monocytes from acute
Charcot patients appear to be specific to this condition. Indeed, both the phenotype of
monocytes from diabetic patients with uncomplicated neuropathy and that of monocytes from
diabetic patients with neuropathy and osteomyelitis-associated foot inflammation was not
different from that of cells from healthy control subjects. This indicates that neither diabetes
nor neuropathy or inflammation, per se, is associated with any modulation of the inflammatory
response of monocytes. Interestingly, we found that all the modification of the immune
phenotype of monocytes disappeared after recovery in patients with acute Charcot. This
suggests that the initiating cause that triggers the inflammatory response in patients with acute
Charcot acts in an environment where mechanisms that physiologically control the intensity
and duration of inflammation are lacking. calcitonin gene-related peptide (CGRP), a 37-amino
acid peptide widely distributed in the central and peripheral nervous systems and mainly in
sensory nerves (Poyner DR et al., 1992), has been shown to inhibit proinflammatory cytokine
production and augment the release of IL-10 by monocytes (Feng Y et al., 1997).
On the other hand, pathogenetic knowledge has focused on purely mechanical theories for
some time. Two theories, initially thought to be competing concepts, are now considered to be
overlapping to varying degrees. On the one hand, the neurotraumatic theory proposes that,
in the presence of sensorimotor neuropathy, abnormal plantar pressure occurs. This is
supported by the amyotrophy of intrinsic muscles, and the imbalance between the extensor
and flexor muscles. In addition, the bones and joints lose their protective sensory capacity,
allowing repetitive trauma that, in turn, leads to excessive extension of the ligaments, and
microfractures and more joint dislocation. On the other hand, the neurovascular theory
suggests that the autonomic neuropathy leads to a hyperaemic state, with an increase in blood
flow to the lower limbs due to the development of arteriovenous shunts. The hyperaemia
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appears to cause osteopenia, bone resorption and bone weakening. Ultimately, it is on this
weakened foot that, either spontaneously or due to minor trauma, microfractures and
dislocations occur.
Although both these theories are attractive, they are not able to explain some of the typical
features of acute Charcot neuro-osteoarthropathy (CN) and, in particular, why the condition
is unilateral while neuropathy is most often bilateral, why CN is so infrequent while neuro‐
pathy is a common complication of diabetes, and what is the link with the inflammatory
reaction that is initially observed.
There is no singular cause for the development of the Charcot foot, but there are factors that
predispose to its development, as well as a number of likely precipitating events. The current
belief is that once the disease is triggered in a susceptible individual, it is mediated through a
process of uncontrolled inflammation in the foot. This inflammation leads to osteolysis and is
indirectly responsible for the progressive fracture and dislocation that characterizes its
presentation (Jeffcoate WJ et al, 2005).
However, as mentioned before, the common link is the local inflammation (Baumhauer et al,
2006) that is associated with the release of proinflammatory cytokines such as interleukin
(IL)-1β and tumour necrosis factor (TNF)-α, which are known mediators of bone resorption
via excess osteoclactic activity (Petrova et al, 2007).
Interestingly, a dissociation between the local inflammatory response related to the increased
proinflammatory cytokine secretion and lack of systemic inflammatory response has been
found in patients with CN (Jeffcoate WJ, 2004).
At the same time, NF-кB induces the increased expression of the glycoprotein osteoprotegerin
(OPG), which acts as a decoy receptor for RANK-L to effectively neutralize its effect and so
avoid excess osteolysis (Fig. 1) (Boyle WJ, 2003).
The role of this pathway in acute CN pathogenesis is supported by the fact that the same
RANK/RANK-L/OPG system is also involved in the process of medial arterial calcification, a
feature that is strongly associated with both the distal symmetrical neuropathy of diabetes
(Jeffcoate WJ, 2009) and CN (Sinha S et al., 1972; Clouse ME et al., 1974).
Nevertheless, a traumatic triggering factor causes the release of inflammatory cytokines that
increase the expression of RANK-L, thereby resulting in clinical signs of inflammation,
osteoclast maturation and activation, and osteolysis. Physiologically, this process is limited by
immobilization in response to the pain caused by local inflammation. However, when pain
perception is reduced due to sensory neuropathy, there is no protective suppression, thereby
allowing the inflammatory process to continue which, in turn, ultimately leads to osteolysis
and bone breakdown. The result is the establishment of a vicious circle of inflammation and
worsening structural damage to the foot (Frykberg RG et al, 2000).
4.1. Diferential diagnosis
While cellulitis may seem to be the likely diagnosis, if a patient with long-standing diabetes,
a history of poor glycemic control, and peripheral neuropathy presents with a red, hot, swollen
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foot with no history of open ulceration, then Charcot neuroarthropathy should be at the top
of the list in the differential diagnosis. Other possibilities include osteomyelitis, acute gout,
cellulitis, abscess, neuropathic fracture, and deep venous thrombosis. However, if the patient
has no open ulceration or history of an open wound, infection is probably not the culprit. Most
diabetic foot infections begin with a direct inoculation through an opening in the skin, such as
a diabetic neuropathic foot ulcer.
4.2. Laboratory tests
There are no laboratory criteria for the diagnosis of Charcot neuroarthropathy and no hema‐
tologic markers, but laboratory testing can help narrow the differential diagnosis. Leukocy‐
tosis, an elevated C-reactive protein and erythrocyte sedimentation rate, and recent
Figure 2. Diagrammatic representation of the RANK/RANK-L/OPG signalling pathway in the process of bone resorp‐
tion. On the one hand, RANK-L (receptor activator of nuclear factor-_B ligand), a surface-bound molecule found on
osteoblasts and bone-marrow stromal cells, binds to its specific membrane-bound receptor RANK (receptor activator
of nuclear factor-_B) at the surface of preosteoclasts and other cells of this lineage. The binding subsequently triggers
a kinase cascade that promotes osteoclast differentiation, activation and survival. On the other hand, OPG (osteopro‐
tegerin), which is also expressed by osteoblasts, acts as a decoy receptor to bind and effectively neutralize RANK-L
which, in turn, limits excess osteoclastogenesis and osteolysis. CFU-GM: colony-forming unit granulocyte–macro‐
phage; M-CSF: monocyte colony-stimulating factor. (L. Molines et al, 2010)
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unexplained hyperglycemia suggest infection. However, unremarkable results on clinical tests
in this population may not com- prehensively exclude infection.
4.3. Imaging studies
Radiographs are the primary initial imaging method for evaluation of the foot in diabetic
patients. Easily available and inexpensive, they provide information on bone structure,
alignment, and mineralization. X-rays may be normal or show subtle fractures and dislocations
or later show more overt fractures and subluxations.
In later stages, the calcaneal inclination angle is reduced and the talo-first metatarsal angle is
broken.
However, radiographic changes of Charcot neuropathic osteoarthropathy (CN) are typically
delayed and have low sensitivity (Morrison WB et al., 2002).
Magnetic resonance imaging (MRI) allows detection of subtle changes in the early stages of
active Charcot neuropathic osteoarthropathy when X-rays could still be normal. MRI primarily
images protons in fat and water and can depict anatomy and pathology in both soft tissue and
bone in great detail. Because of its unique capability of differentiating tissues with high detail,
MRI has a high sensitivity and specificity for osteomyelitis and has become the test of choice
for evaluation of the complicated foot in diabetic patients (Morrison WB et al., 2001).
Although not required for diagnosis when X-rays are diagnostic for Charcot bone and joint
changes, MRI is very useful in making the diagnosis at its earliest onset before such changes
become evident on plain films. Nuclear medicine includes a number of exams based on the
use of radioisotopic tracers. Three-phase bone scans, based on technetium-99m (99mTc), are
highly sensitive for active bone pathology. However, diminished circulation can result in false-
negative exams and, perhaps more importantly, uptake is not specific for osteoarthropathy.
Labeled white blood cell scanning (using 111In or 99mTc) provides improved specificity for
infection in the setting of neuropathic bone changes but it can be difficult to differentiate soft
tissue from bone (Keidar Z et al., 2005; Palestro CJ et al., 1998)
More recently, positron emission tomography scanning has been recognized as having
potential for diagnosis of infection and differentiating the Charcot foot from osteomyelitis
(Hopfner S et al., 2005). However, this remains investigational at this time. Evaluation of bone
mineral density (BMD) may be useful in those with diabetes to assess onset of CN as well as
fracture risk. BMD can be assessed using dual-energy X-ray absorptiometry or calcaneal
ultrasound. (Frykberg RG et al., 2010).
Experts agree that radiographs are important as the first exam in virtually all settings (Hopfner
S et al., 2005;). However, a negative result obviously should not offer any confidence regarding
lack of disease.
The MRI is very effective at excluding osseous disease. If the patient has anulceration with a
high likelihood of deep infection, MRI is the best diagnostic modality. The decision of nuclear
imaging versus MRI is largely based on personal preference, availability, and local experience.
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In general, if metal is present in the foot, nuclear medicine exams are preferred, whereas diffuse
or regional ischemia makes MRI the preferred exam.
The diagnosis of active Charcot foot is primarily based on history and clinical findings but
should be confirmed by imaging. Inflammation plays a key role in the pathophysiology of the
Charcot foot and is the earliest clinical finding. The X-rays should be the initial imaging
performed, and one should look for subtle fractures or subluxations if no obvious pathology
is visible. MRI or nuclear imaging can confirm clinical suspicions in the presence of normal-
appearing radiographs. (Lee C et al., 2011).
In the other hand, Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose
is also gaining support, especially when combined with computed tomography (CT). This PET-
CT hybrid has better anatomic localization than PET alone.
PET-CT is very reliable for differentiating Charcot neuroarthropathy from osteomyelitis, a
distinction that can be difficult to make when Charcot neuroarthropathy is complicated by
adjacent loss of skin integrity. The sensitivity of PET-CT in this situation has been reported as
100%, and its sensitivity 93.8%.22.
5. Treatment
The goals of treatment for acute or quiescent Charcot neuroarthropathy should be to maintain
or achieve structural stability of the foot and ankle, to prevent skin ulceration, and to preserve
the plantigrade shape of the foot so that prescription footwear can be used.
Immobilization: A total-contact cast is worn until the redness, swelling, and heat subside,
generally 8 to 12 weeks, after which the patient should use removable braces or a Charcot re-
straint orthotic walker for a total of 4 to 6 months of treatment. Many physicians also recom‐
mend elastic stockings (eg, Stockinette) or an elastic tubular bandage (eg, Tubigrip) to reduce
edema under the cast.
6. Drug therapy
Due to bone mineral density alterations in CN patients manifested by localized osteopenic
changes, bisphosphonates have been tested for their benefit with off-loading in Stage I.
Bisphosphonates are pyrophosphate analogs that inhibit osteoclastic bone resorption and are
commonly used in treatment of conditions characterized by abnormal bone turnover. Pamidr‐
onate is the most commonly used and acts by attaching onto hydroxyapatite crystals in newly
synthesized bone matrix, blocking access of osteoclast precursors to this matrix. (Jude EB et
al., 2001) performed a randomized double-blind placebo-controlled 39 patients with active
Charcot in which a single 90 mg pamidronate infusion was administered and standard off-
loading provided while foot temperatures, symptoms, and bone turnover markers were
measured over 1-year. There was a statistically significant reduction in bone turnover,
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symptoms, and disease activity. Similarly, (Pitocco et al., 2005) showed significant reduction
in bone resorption markers with the use of another bisphosphonate alendronate and noted
clinical improvements in the CN foot at 6 months. Some clinicians also prescribe bisphosph‐
onates in the early stages of treatment, as the bone mineral density of the affected foot is low.
Unfortunately, while these drugs can significantly reduce the levels of bone turnover markers,
temperature, and pain, evidence of clinical benefit such as an earlier return to ambulation or
radiographic improvement is weak at best.
Figure 3. Neuro-osteoarthropathy of Charcot foot
Surgery is reserved for severe ankle and midfoot deformities that are susceptible to skin
ulcerations and that make braces and orthotic devices difficult to use.
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7. New insights on treatment
Similarly, use of calcitonin and non-steroidal anti-inflammatory drugs has been reported as
adjunct treatment to conventional therapy. Recently, new anti-inflammatory therapeutic
agents such as corticosteroids, TNF-α antagonists (infliximab, etanercept) and RANK-L
antagonists (denosumab) have been proposed, but further research is needed.
Another potential therapeutic agents that also have a direct effect on the RANK-L/OPG system
in addition to calcitonin are inhibitors of tumor necrosis factor- α (TNF- α), glucocorticoids
and non-steroidal anti-inflammatories, (Jeffcoate WJ et al., 2005) has also mentioned other
future options including synthetic OPG and RANK-L antagonists and other inhibitors of NF-
kB and TNF-α like diacerein.
Diacerein is another medication used frequently in the treatment of some articular diseases as
a result of its effect on the inflammatory process. Diacerein decreases cytokine concentrations,
in particular, TNF- α and IL-1b and it could be one of the most promising strategies in the
current treatment of the acute phase of the diabetic Charcot foot.
Diacerein (9,10-dihydro-4,5-bis(acetyloxy)9,10-dioxo-2-anthracene carboxylic acid) is one of
symptomatic slow-acting drugs in osteoarthritis (SYSADOA) for the treatment of OA (Bruyère
O et al., 2008). After oral administration, it is rapidly broken down and deacetylated into its
active metabolite, rhein, (Spencer CM., 1997). The potential disease modifying properties of
diacerein and its metabolite have been shown in vitro and in vivo models to be primarily due
to potent inhibition of the production and activity of inflammatory cytokines and other
catabolic cytokines expressed in OA and in CN, which are involved in cartilage catabolism
and also may induce the apoptosis of chondrocytes (De Isla NG et al, 2008; Tamura T et al., 2001)
In addition to this, Briefly, activation of osteoclasts involved in osteolysis is accomplished by
the nuclear transcription factor NF- kB. The expression of NF-kB is induced by the cytokine
RANK-L, which is accompanied by increased production of osteoprotegerin (OPG). The
RANK-L/OPG system’s theoretical role in osteopenia associated with diabetic neuropathy led
to the development and use of intranasal salmon calcitonin for treatment of acute CN. A
randomized controlled trial by (Bem et al., 2006) was performed on 32 acute CN patients
administered 200 IU daily, showing reduction in markers of bone turnover as well as a
decreased time to healing. This therapy has shown fewer complications compared to bi‐
sphosphonate use.
8. Conclusion
Conservative options continue to evolve in their indications for the treatment of the CN foot
and ankle. The modalities discussed within this chaspter provide a wide variety of options;
yet, a further higher level of evidence studies is warranted. There is no doubt that there are
specific indications for conservative management versus surgical. Regardless of the chosen
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treatment pathway, all protocols should be specific to the patient based on their lower
extremity pathology, overall medical status, and ability to comply with the given therapy.
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